Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients.
According to Atossa, the patent strengthens its (Z)-endoxifen portfolio and encompasses novel compositions and methods related to (Z)-endoxifen, specifically enteric oral formulations and salts as well as their use in treating hormone-dependent breast and reproductive tract disorders.
In a statement, Steven Quay, MD, Ph.D., president and CEO of Atossa, said, “The issuance of U.S. Patent No. 12,275,684 marks a significant milestone in our mission to advance innovative treatments for breast cancer. This patent not only reinforces our commitment to protecting our intellectual property but also underscores our dedication to delivering effective therapeutic options to patients. We remain steadfast in our pursuit of scientific excellence and patient-centered solutions to address the persisting unmet medical needs in breast cancer treatment and prevention.”
